Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOFLURANE vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isoflurane is a general inhalation anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits excitatory receptors such as NMDA and AMPA receptors. It potentiates inhibitory neurotransmission and depresses excitatory neurotransmission, leading to anesthesia, amnesia, and muscle relaxation.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Induction and maintenance of general anesthesia,Sedation in mechanically ventilated patients (off-label)
Mild to moderate pain,Fever
Induction: 1-3% in oxygen or oxygen/nitrous oxide mixture via inhalation; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture via inhalation.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is approximately 2.5 to 5 hours. Context: The context-sensitive half-time varies with duration of anesthesia; for short procedures (<1 hour), half-life is about 2-4 minutes, but for prolonged anesthesia, it can be 30-60 minutes due to redistribution from fat stores.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Isoflurane undergoes minimal metabolism (approximately 0.2%) primarily via hepatic cytochrome P450 enzymes (CYP2E1), leading to the production of inorganic fluoride and trifluoroacetic acid. The major route of elimination is via exhalation as unchanged drug.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily eliminated via exhalation through the lungs (>99%). Less than 1% undergoes hepatic metabolism to trifluoroacetic acid and fluoride ions, which are excreted renally.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 5-20% bound to plasma proteins, primarily albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution is about 2-5 L/kg, reflecting extensive tissue distribution, especially to lipid-rich tissues like brain and fat.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Inhalation: Bioavailability is essentially 100% for inspired drug; systemic absorption is nearly complete due to rapid pulmonary exchange.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No dose adjustment required in renal impairment; pharmacokinetics unaffected.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No specific dose adjustment guidelines; use with caution in severe hepatic impairment due to potential for hepatotoxicity.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Induction: 1.5-3% in oxygen or oxygen/nitrous oxide mixture; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture; titrate to effect.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Reduce concentrations by 20-50% due to increased sensitivity and decreased MAC; monitor hemodynamics closely.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Because isoflurane is a potent halogenated anesthetic, it may cause malignant hyperthermia, a life-threatening condition characterized by hypermetabolism, muscle rigidity, tachycardia, and hyperthermia. Immediate treatment with dantrolene and discontinuation of triggering agents is essential.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of malignant hyperthermia,Respiratory depression,Hypotension and myocardial depression,Elevated intracranial pressure,Hepatic injury (rare),Nephrotoxicity due to fluoride ion (rare),QT interval prolongation,Use with caution in patients with coronary artery disease
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Known or suspected susceptibility to malignant hyperthermia,Prior history of unexplained jaundice or fever after isoflurane administration,Concurrent use of entacapone (increased risk of intraoperative myocardial depression)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No specific food interactions with isoflurane. However, fasting before anesthesia is required to reduce the risk of pulmonary aspiration.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Isoflurane is not associated with major congenital malformations but may cause fetal depression, especially during third trimester. Avoid elective use until after delivery.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Minimal transfer into breast milk; M/P ratio unknown. Considered compatible with breastfeeding after single exposure; observe infant for sedation.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No dose adjustment required for pregnancy per se; however, MAC decreases by about 25-40% during pregnancy due to hormonal changes and increased progesterone. Use lowest effective dose.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Isoflurane is a halogenated ether anesthetic. It causes dose-dependent hypotension primarily through vasodilation. It is not recommended for induction in pediatrics due to pungency and airway irritability. Malignant hyperthermia trigger. Use with caution in patients with elevated intracranial pressure as it can increase cerebral blood flow. Monitor end-tidal CO2 and volatile agent concentration.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
You will receive isoflurane gas to keep you asleep and pain-free during surgery.,You may experience shivering or nausea after awakening; tell your nurse if severe.,Do not eat or drink for the time instructed before surgery to prevent aspiration.,If you have a personal or family history of malignant hyperthermia, inform your anesthesiologist immediately.,Arrange for a ride home after surgery as isoflurane can impair coordination and judgment for up to 24 hours.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Telithromycin, a macrolide antibiotic, prolongs the QT interval by blocking the rapid component of the delayed rectifier potassium current (IKr). Isoflurane, a volatile anesthetic, also prolongs the QT interval via inhibition of IKr and other cardiac ion channels. The combination may lead to additive or synergistic QT prolongation, increasing the risk of torsades de pointes, a potentially fatal ventricular arrhythmia, especially in patients with other risk factors such as hypokalemia, bradycardia, or pre-existing cardiac disease."
"Isoflurane, a volatile halogenated anesthetic, potentiates the cardiodepressant and arrhythmogenic effects of levobupivacaine, a long-acting amide local anesthetic, by inhibiting myocardial calcium channels and β-adrenergic responsiveness. This additive negative inotropic and chronotropic effect increases the risk of hypotension, bradycardia, and potentially life-threatening ventricular arrhythmias during combined use. Additionally, isoflurane may delay levobupivacaine metabolism by reducing hepatic blood flow, prolonging systemic exposure and toxicity."
"The combination of isoflurane and thiamylal results in synergistic CNS depression and enhanced negative inotropic and vasodilatory effects on the cardiovascular system. Isoflurane potentiates the barbiturate-induced suppression of myocardial contractility and baroreceptor reflexes, leading to a heightened risk of hypotension, bradycardia, and reduced cardiac output. Clinically, patients may experience profound anesthesia, prolonged recovery, and hemodynamic instability, especially during induction and maintenance of anesthesia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOFLURANE vs ACEPHEN, answered by our medical review team.
ISOFLURANE is a Inhalational Anesthetic that works by Isoflurane is a general inhalation anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits excitatory receptors such as NMDA and AMPA receptors. It potentiates inhibitory neurotransmission and depresses excitatory neurotransmission, leading to anesthesia, amnesia, and muscle relaxation.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOFLURANE and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOFLURANE is: Induction: 1-3% in oxygen or oxygen/nitrous oxide mixture via inhalation; Maintenance: 0.5-2% in oxygen or oxygen/nitrous oxide mixture via inhalation.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOFLURANE and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOFLURANE is classified as Category C. Isoflurane is not associated with major congenital malformations but may cause fetal depression, especially during third trimester. Avoid elective use until after delivery.. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.